Skip to Main Content

INFORMATION FOR

An Exploratory Phase 1b Open-label Multi-arm Trial to Evaluate the Safety and Efficacy of CC-90009 in Combination With Anti-Leukemia Agents in Subjects With Acute Myeloid Leukemia

Conditions

Myeloid and Monocytic Leukemia

Phase I

What is the purpose of this trial?

CC-90009-AML-002 is an exploratory Phase 1b, open-label, multi-arm trial to evaluate the safety and efficacy of CC-90009 in combination with anti-leukemia agents in participants with acute myeloid leukemia (AML).

  • Trial with
    Celgene Corporation
  • Start Date
    09/22/2022
  • End Date
    04/28/2023

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    11/15/2022
  • Study HIC
    #2000027204